HC Wainwright & Co. Reiterates Buy on Telix Pharmaceuticals, Maintains $20 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 83.0%

Neg 0% Neu 83% Pos 0%

HC Wainwright & Co. analyst Robert Burns reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Buy and maintains $20 price target.